Last week marked the announcement of the shortlist for the Pharma Industry Awards 2017. Over the last four years since the awards’ inception in 2014, there’s been a very interesting evolution and mix of organisations who have featured in the shortlist. This isn’t simply an exercise in giving big pharma a pat on the back, but a recognition of the individuals and teams within these large pharma companies that make a real difference. It’s also become synonymous with recognising the next generation of companies in the Irish market.
In the last few years APC, led by CEO and Co-Founder Mark Barrett has taken home three awards. APC has gone on to open a 30,000sqft R&D unit in Cherrywood, growing 60 to 70 percent in 2017 to over €20m in revenue. This year sees Valitacell, an exciting company based out of NIBRT in UCD enter the fray. Nominated for three awards, including the Pharma Company of the Year – SME, this highly innovative company develops biotechnology which allows companies to deliver faster and cheaper processing of bio-therapeutic drugs. This could be a game changer in an ever more complex and costly regulatory environment.
The mainstays of Pfizer, Amgen and AbbVie are again in contention across a plethora of awards. However, I suspect that they are all hoping to beat each other out for the coveted prize of Pharma Company of the Year – Large.
In addition to this, and possibly more importantly, it’s a great opportunity to connect with the wider pharma community. All too often we become very insular in our outlook as we get bogged down in the day to day running of our own businesses. Connecting with the wider industry allows us to see the bigger picture, share ideas, experiences and insights. With few opportunities to do this, the Pharma Awards are one of the few events in the calendar that allow us to do just that.
For a list of those shortlisted for the awards, please click here.
Accreate will be attending the event in force, so please do pop over for a chat if you are in attendance!